Entrada Therapeutics (TRDA)
Applies a cyclic-peptide delivery platform to exon-skipping therapies for Duchenne muscular dystrophy and myotonic dystrophy.
$6.40
vs last close−0.32 (−4.69%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
estimated · in 43 days
EPS estimate
−$0.98
Revenue estimate
$2.1M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$0.03−$0.42−$1.04−$1.06−$0.94−$0.95−$1.01Pending
Estimate−$0.66−$0.78−$0.86−$1.04−$1.32−$1.06−$0.97−$0.98
Surprise+104.5%+46.2%−20.9%−1.9%+28.8%+10.4%−3.7%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$37.4M$20.6M$2.0M$1.6M$1.3M$875.0K$898.0KPending
Estimate$13.1M$9.8M$7.8M$8.5M$7.4M$2.9M$2.3M$2.1M
Surprise+185.0%+110.4%−75.1%−81.0%−82.5%−70.0%−61.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2030 | −$0.70 | — | — |
| Sep 2030 | −$0.60 | — | — |
| Jun 2030 | $0.20 | — | — |
| Mar 2030 | −$0.60 | — | — |
| Dec 2029 | −$0.90 | — | — |
| Sep 2029 | −$0.90 | — | — |
| Jun 2029 | −$0.80 | — | — |
| Mar 2029 | −$0.10 | — | — |
| Dec 2028 | −$0.97 | — | — |
| Sep 2028 | −$0.94 | — | — |
| Jun 2028 | −$0.97 | — | — |
| Mar 2028 | −$0.66 | — | — |
| Dec 2027 | −$0.85 | — | — |
| Sep 2027 | −$0.86 | — | — |
| Jun 2027 | −$0.83 | — | — |
| Mar 2027 | −$0.76 | — | — |
| Dec 2026 | −$0.93 | — | — |
| Nov 2026 | −$0.98 | — | — |
| Aug 2026 | −$0.97 | −$1.01 | −3.7% |
| May 2026 | −$1.06 | −$0.95 | +10.4% |
| Feb 2026 | −$1.32 | −$0.94 | +28.8% |
| Nov 2025 | −$1.04 | −$1.06 | −1.9% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Nov 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2030 | −$0.70 | — | — | $9.9M | — | — | — |
| Sep 2030 | −$0.60 | — | — | $7.1M | — | — | — |
| Jun 2030 | $0.20 | — | — | $90.9M | — | — | — |
| Mar 2030 | −$0.60 | — | — | $4.1M | — | — | — |
| Dec 2029 | −$0.90 | — | — | $3.2M | — | — | — |
| Sep 2029 | −$0.90 | — | — | $1.2M | — | — | — |
| Jun 2029 | −$0.80 | — | — | $800.0K | — | — | — |
| Mar 2029 | −$0.10 | — | — | $60.7M | — | — | — |
| Dec 2028 | −$0.97 | — | — | $696.1K | — | — | — |
| Sep 2028 | −$0.94 | — | — | $892.2K | — | — | — |
| Jun 2028 | −$0.97 | — | — | $892.2K | — | — | — |
| Mar 2028 | −$0.66 | — | — | $22.9M | — | — | — |
| Dec 2027 | −$0.85 | — | — | $3.7M | — | — | — |
| Sep 2027 | −$0.86 | — | — | $3.5M | — | — | — |
| Jun 2027 | −$0.83 | — | — | $2.8M | — | — | — |
| Mar 2027 | −$0.76 | — | — | $11.6M | — | — | — |
| Dec 2026 | −$0.93 | — | — | $7.0M | — | — | — |
| Nov 5, 2026 | −$0.98 | — | — | $2.1M | — | — | — |
| Aug 5, 2026 | −$0.97 | −$1.01 | −3.7% | $2.3M | $898.0K | −61.4% | −2.5% |
| May 7, 2026 | −$1.06 | −$0.95 | +10.4% | $2.9M | $875.0K | −70.0% | −57.3% |
| Feb 26, 2026 | −$1.32 | −$0.94 | +28.8% | $7.4M | $1.3M | −82.5% | +6.8% |
| Nov 6, 2025 | −$1.04 | −$1.06 | −1.9% | $8.5M | $1.6M | −81.0% | +0.1% |
| Aug 6, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 5, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 7, 2024 | |||||||
| Mar 13, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 10, 2023 | |||||||
| Mar 6, 2023 | |||||||
| Nov 7, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 15, 2022 | |||||||
| Dec 9, 2021 | |||||||
| Nov 1, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 |